Benitec Biopharma Limited (NASDAQ:BNTC) Receives $26.00 Average Target Price from Brokerages

Shares of Benitec Biopharma Limited (NASDAQ:BNTC) have earned an average recommendation of “Buy” from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $26.00.

BNTC has been the subject of a number of analyst reports. TD Cowen started coverage on Benitec Biopharma in a research report on Monday, July 7th. They set a “buy” rating for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $20.00 price objective on shares of Benitec Biopharma in a report on Thursday, May 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $28.00 target price on shares of Benitec Biopharma in a research report on Monday, May 19th.

Benitec Biopharma Price Performance

NASDAQ BNTC opened at $12.66 on Tuesday. The company has a 50-day moving average price of $12.99 and a two-hundred day moving average price of $13.05. Benitec Biopharma has a 52 week low of $8.06 and a 52 week high of $17.15. The stock has a market cap of $332.33 million, a price-to-earnings ratio of -8.38 and a beta of 0.40. The company has a current ratio of 14.80, a quick ratio of 14.80 and a debt-to-equity ratio of 0.01.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.12. Analysts forecast that Benitec Biopharma will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Benitec Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Benitec Biopharma in the second quarter valued at $93,000. Marshall Wace LLP acquired a new stake in shares of Benitec Biopharma during the second quarter worth $503,000. New York State Common Retirement Fund acquired a new stake in shares of Benitec Biopharma during the second quarter worth $95,000. XTX Topco Ltd purchased a new stake in shares of Benitec Biopharma during the second quarter valued at $127,000. Finally, Rhumbline Advisers boosted its position in shares of Benitec Biopharma by 11,114.0% in the 2nd quarter. Rhumbline Advisers now owns 20,858 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 20,672 shares during the period. 52.19% of the stock is owned by institutional investors and hedge funds.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.